文章：

施拉芬蛋白：新兴的治疗靶点

Schlafens: Emerging Therapeutic Targets

原文发布日期：9 May 2024

DOI: 10.3390/cancers16101805

类型: Article

开放获取: 是

英文摘要：

The interferon (IFN) family of immunomodulatory cytokines has been a focus of cancer research for over 50 years with direct and indirect implications in cancer therapy due to their properties to inhibit malignant cell proliferation and modulate immune responses. Among the transcriptional targets of the IFNs is a family of genes referred to as Schlafens. The products of these genes, Schlafen proteins, exert important roles in modulating cellular proliferation, differentiation, immune responses, viral replication, and chemosensitivity of malignant cells. Studies have demonstrated that abnormal expression of various Schlafens contributes to the pathophysiology of various cancers. Schlafens are now emerging as promising biomarkers and potentially attractive targets for drug development in cancer research. Here, we highlight research suggesting the use of Schlafens as cancer biomarkers and the rationale for the development of specific drugs targeting Schlafen proteins.

摘要翻译： 

干扰素（IFN）作为一类免疫调节细胞因子，因其具有抑制恶性细胞增殖和调节免疫应答的特性，在癌症治疗中具有直接和间接的应用价值，五十多年来一直是癌症研究的重点。干扰素的转录靶标中包含一组被称为Schlafen的基因家族。这些基因的产物——Schlafen蛋白——在调节细胞增殖、分化、免疫应答、病毒复制以及恶性细胞的化疗敏感性方面发挥着重要作用。研究表明，多种Schlafen蛋白的异常表达与多种癌症的病理生理过程密切相关。目前，Schlafen蛋白正逐渐成为癌症研究中极具潜力的生物标志物，并有望成为药物开发的理想靶点。本文重点综述了将Schlafen蛋白作为癌症生物标志物的相关研究，并阐述了开发靶向Schlafen蛋白特异性药物的理论基础。

原文链接：

Schlafens: Emerging Therapeutic Targets